author-photo

Marie-Pierre Galais

62

Papers

1477

Citations

Citation Trend

Filter By

Papers (46) Sort By

Journal Conference Others

Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Interim analysis of a phase II study of simultaneously integrated boost intensity modulated radiation therapy (SIB-IMRT) in combination with 5-FU and mitomycin-C among patients with locally advanced anal canal cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).

2020 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (2)
Optimisation of chemotherapy prescription and preparation in an ambulatory unit: Validation of the OPTIMA program

2019 European Journal of Cancer Care
Show All
- Source
- Cite
- Save
Citations (1)
Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)

2019 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (8)
Digestive and genitourinary sequelae in rectal cancer survivors and their impact on health-related quality of life: Outcome of a high-resolution population-based study

2019 Surgery
Show All
- Source
- Cite
- Save
Citations (9)
Withholding the Introduction of Anti‐Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild‐Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)

2019 Oncologist
Show All
- Source
- Cite
- Save
Citations (2)
485PWithholding Anti-EGFR: Impact on outcome of RAS wild-type metastatic colorectal tumours (WAIT OR ACT): A multicentric AGEO study

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Utility of serum anti‐cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab

2017 British Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (11)
Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer

2017 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (15)